Monograph Details
|
|
Respiratory Tract
> Asthma/COPD
|
|
FLOVENT HFA |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Steroid. |
| Generic Name |
|
Fluticasone propionate 44 micrograms/inh, 110 micrograms/inh, 220 micrograms/inh; metered dose inhaler; CFC-free. |
| Indications |
|
Maintenance treatment of asthma as prophylactic therapy. Asthma requiring systemic corticosteroid therapy, to reduce need for oral systemic corticosteroids. |
| Children |
|
<4yrs: not recommended. 4–11yrs: 88mcg twice daily. Rinse mouth after use. |
| Adults |
|
Previously on bronchodilators alone: initially 88mcg twice daily; max 440mcg twice daily. Previously on inhaled corticosteroids: initially 88–220mcg twice daily; max 440mcg twice daily. Previously on oral corticosteroids (wean gradually): initially 440mcg twice daily; max 880mcg twice daily. Rinse mouth after use. |
| Contraindications |
|
Not for primary treatment of acute attack. |
| Precautions |
|
Maintain regular regimen. Infections. If exposed to chickenpox or measles, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually). Hepatic impairment (monitor). Transferring from oral corticosteroids: see literature. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Avoid ritonavir. Caution with potent CYP3A4 inhibitors (eg, ketoconazole). |
| Adverse Reactions |
|
Local effects (pharyngitis, nasal congestion/discharge, rhinitis, dysphonia, sinusitis, oral candidiasis), upper respiratory infection, headache, influenza, bronchospasm. |
| How Supplied |
Inhaler w. actuator (44mcg)—10.6g (120 inh)
110mcg, 220mcg—12g (120 inh) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
